Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126154171 | 12615417 | 1 | I | 201511 | 20160725 | 20160802 | 20160802 | EXP | FR-ELI_LILLY_AND_COMPANY-FR201607011111 | ELI LILLY AND CO | 68.00 | YR | M | Y | 0.00000 | 20160801 | CN | FR | FR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126154171 | 12615417 | 1 | PS | ALIMTA | PEMETREXED DISODIUM | 1 | Intravenous (not otherwise specified) | UNK, UNKNOWN | N | U | 21462 | INJECTION | |||||||
| 126154171 | 12615417 | 2 | SS | ALIMTA | PEMETREXED DISODIUM | 1 | Intravenous (not otherwise specified) | 825 MG, UNKNOWN | N | U | 21462 | 825 | MG | INJECTION | |||||
| 126154171 | 12615417 | 3 | SS | CISPLATINE | CISPLATIN | 1 | U | 0 | |||||||||||
| 126154171 | 12615417 | 4 | SS | AVASTIN | BEVACIZUMAB | 1 | U | 0 | |||||||||||
| 126154171 | 12615417 | 5 | SS | FLAGYL | METRONIDAZOLEMETRONIDAZOLE HYDROCHLORIDE | 1 | Unknown | 500 MG, BID | N | 0 | 500 | MG | BID |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126154171 | 12615417 | 1 | Pleural mesothelioma |
| 126154171 | 12615417 | 2 | Malignant neoplasm progression |
| 126154171 | 12615417 | 3 | Pleural mesothelioma |
| 126154171 | 12615417 | 4 | Pleural mesothelioma |
| 126154171 | 12615417 | 5 | Anal fissure |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126154171 | 12615417 | HO |
| 126154171 | 12615417 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126154171 | 12615417 | Anal fissure | |
| 126154171 | 12615417 | Dermatitis exfoliative | |
| 126154171 | 12615417 | Hepatocellular injury | |
| 126154171 | 12615417 | Malignant neoplasm progression | |
| 126154171 | 12615417 | Off label use | |
| 126154171 | 12615417 | Pyrexia | |
| 126154171 | 12615417 | Rash maculo-papular |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126154171 | 12615417 | 1 | 201511 | 0 | ||
| 126154171 | 12615417 | 2 | 20160629 | 0 | ||
| 126154171 | 12615417 | 5 | 20160702 | 20160706 | 0 |